To include your compound in the COVID-19 Resource Center, submit it here.

Antibiotic engine

Entasis taps non-dilutive and series B-1 funds to advance antibiotics trio

A combination of non-dilutive funding and a newly-raised $31.9 million series B-1 round should give Entasis Therapeutics Inc. enough cash to see its lead candidate all the way through commercialization and to move two others to their next milestones.

The company's B-1 extension round closed on

Read the full 467 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE